Patents by Inventor Rory A. Capstick

Rory A. Capstick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230303552
    Abstract: Arylsulfonamides of carboxamido-piperidines, -pyrrolidines, and -azetidines, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment of psychiatric disorders such as substance-related misuse, substance- related disorder relapse, anxiety, depression, and psychosis.
    Type: Application
    Filed: June 18, 2021
    Publication date: September 28, 2023
    Inventors: Andrew S. Felts, Changho Han, Rory A. Capstick, Douglas L. Orsi, David L. Whomble, Craig W. Lindsley, P. Jeffrey Conn
  • Publication number: 20230183237
    Abstract: Arylsulfonamides of 4-heteroaryl-piperidines, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment of psychiatric disorders such as substance-related misuse, substance-related disorder relapse, anxiety, depression, and psychosis.
    Type: Application
    Filed: May 21, 2021
    Publication date: June 15, 2023
    Inventors: Craig W. Lindsley, Carrie K. Jones, P. Jeffrey Conn, Changho Han, Andrew S. Felts, Douglas L. Orsi, Julie L. Engers, Jinming Li, Rory A. Capstick, David L. Whomble, Kayla J. Temple
  • Patent number: 11427573
    Abstract: Indazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: August 30, 2022
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Andrew S. Felts, Colleen M. Niswender, Rory A. Capstick, Paul K. Spearing, Sean R. Bollinger
  • Publication number: 20220259190
    Abstract: Indazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.
    Type: Application
    Filed: April 26, 2022
    Publication date: August 18, 2022
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Andrew S. Felts, Colleen M. Niswender, Rory A. Capstick, Paul K. Spearing, Sean R. Bollinger
  • Patent number: 11319304
    Abstract: Pyridine quinoline compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: May 3, 2022
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Andrew S. Felts, Colleen M. Niswender, Rory A. Capstick, Paul K. Spearing, Sean R. Bollinger
  • Patent number: 10961253
    Abstract: Disclosed herein are pyrido[3?,2?:4,5]thieno[3,2-d]pyrimidine and pyrimido[4?,5?:4,5]thieno[2,3-c]pyridazine compounds, which may be useful as positive allostenc modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: March 30, 2021
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, Darren W. Engers, P. Jeffrey Conn, Katrina A. Bollinger, Rory Capstick, Paul Spearing, Sean R. Bollinger
  • Publication number: 20200291019
    Abstract: Indazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.
    Type: Application
    Filed: August 16, 2018
    Publication date: September 17, 2020
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Andrew S. Felts, Colleen M. Niswender, Rory A. Capstick, Paul K. Spearing, Sean R. Bollinger
  • Publication number: 20200165232
    Abstract: Pyridine quinoline compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.
    Type: Application
    Filed: June 28, 2018
    Publication date: May 28, 2020
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Andrew S. Felts, Colleen M. Niswender, Rory A. Capstick, Paul K. Spearing, Sean R. Bollinger
  • Patent number: 10508105
    Abstract: Indazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: December 17, 2019
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Andrew S. Felts, Colleen M. Niswender, Rory A. Capstick, Paul K. Spearing, Sean R. Bollinger
  • Publication number: 20190330225
    Abstract: Disclosed herein are pyrido[3?,2?:4,5]thieno[3,2-d]pyrimidine and pyrimido[4?,5?:4,5]thieno[2,3-c]pyridazine compounds, which may be useful as positive allostenc modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
    Type: Application
    Filed: November 7, 2017
    Publication date: October 31, 2019
    Inventors: Craig W. Lindsley, Darren W. Engers, P. Jeffrey Conn, Katrina A. Bollinger, Rory Capstick, Paul Spearing, Sean R. Bollinger
  • Publication number: 20190055225
    Abstract: Indazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.
    Type: Application
    Filed: August 16, 2018
    Publication date: February 21, 2019
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Andrew S. Felts, Colleen M. Niswender, Rory A. Capstick, Paul K. Spearing, Sean R. Bollinger